Hims & Hers health COO Melissa Baird sells $2.36m in stock

Melissa Baird, Chief Operating Officer of Hims & Hers Health, Inc. (NYSE:HIMS), has sold shares worth approximately $2.36 million, according to a recent SEC filing. The transactions, which took place on March 26, involved the sale of 67,687 shares of Class A common stock at prices ranging from $33.57 to $37.35 per share.

In addition to these sales, Baird exercised stock options to acquire 67,687 shares at an exercise price of $0.40 per share. Following these transactions, Baird holds 751,243 shares of the company directly. The stock currently trades at $31.92, down from its recent close of $37.04, though InvestingPro data shows management has been actively buying back shares, signaling confidence in the company’s outlook.

These transactions were conducted under a Rule 10b5-1 trading plan, which Baird adopted on May 30, 2024. This plan allows company insiders to set up a predetermined schedule for buying or selling stock, helping to avoid potential accusations of insider trading. For deeper insights into HIMS’s insider trading patterns and 14+ additional ProTips, explore the comprehensive Pro Research Report available on InvestingPro.

In other recent news, Hims & Hers Health, Inc. has seen significant developments affecting its business and investor outlook. The company’s first-quarter online revenue for 2025 is projected to be between $594 million and $622 million, reflecting a substantial year-over-year growth of 122% to 132%, according to BofA Securities. This projection surpasses the Visible Alpha consensus of $523.9 million. BofA Securities analyst Michael Cherny raised the stock price target to $22, citing accelerated growth in GLP-1 sales, although he maintained an Underperform rating due to potential risks associated with semaglutide, a key sales driver. The Food and Drug Administration (FDA) has extended enforcement discretion for compounding semaglutide until April 2025, providing regulatory clarity for Hims & Hers.

Meanwhile, Citi analyst Daniel Grosslight reiterated a Sell rating with a $27 target, amid ongoing legal challenges concerning the medication tirzepatide. The Texas Northern District Court’s decision to uphold the FDA’s removal of tirzepatide from the drug shortage list could influence Hims & Hers’ operations. Grosslight expressed skepticism about the success of appeals against this ruling, suggesting potential implications for the company’s business model. As the legal proceedings continue, the outcome may affect investor sentiment and Hims & Hers’ strategic direction.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.